NEUROPHET Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	2,562	2,615	2,216
Revenue Growth (YoY)	-	18.00%	-
Cost of Revenue	-5.38	3.91	1.27
Gross Profit	2,568	2,611	2,215
Selling, General & Admin	12,886	12,337	9,739
Research & Development	5,893	5,276	5,987
Amortization of Goodwill & Intangibles	146.76	148.53	141.42
Other Operating Expenses	87.52	108.99	62.28
Operating Expenses	20,338	19,160	16,864
Operating Income	-17,771	-16,549	-14,649
Interest Expense	-403.58	-920.64	-3,614
Interest & Investment Income	485.27	413.26	468.72
Currency Exchange Gain (Loss)	-1.41	-9.89	-17.5
Other Non Operating Income (Expenses)	-5,606	-5,323	2,713
EBT Excluding Unusual Items	-23,296	-22,389	-15,098
Gain (Loss) on Sale of Assets	-0.2	-0.08	-3.48
Pretax Income	-23,297	-22,389	-15,101
Net Income	-23,297	-22,389	-15,101
Net Income to Common	-23,297	-22,389	-15,101
Shares Outstanding (Basic)	11	10	4
Shares Outstanding (Diluted)	11	10	4
Shares Change (YoY)	-	163.51%	-
EPS (Basic)	-2109.07	-2301.74	-4091.00
EPS (Diluted)	-2109.07	-2301.74	-4091.00
Free Cash Flow	-16,279	-15,332	-12,862
Free Cash Flow Per Share	-1473.79	-1576.25	-3484.24
Gross Margin	100.21%	99.85%	99.94%
Operating Margin	-693.52%	-632.84%	-660.98%
Profit Margin	-909.17%	-856.15%	-681.41%
Free Cash Flow Margin	-635.32%	-586.30%	-580.35%
EBITDA	-16,644	-15,439	-13,554
D&A For EBITDA	1,126	1,110	1,095
EBIT	-17,771	-16,549	-14,649
Advertising Expenses	-	799.23	919.06